Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Feb 20, 2019 4:00pm

84 Views

Post# 29390181

RE:RE:RE:RE:RE:RE:RE:RE:RE:CC

bigd1986 wrote: Just after the initial delay for approval so like early November 2017, I went to a lunch in Montreal during which luc was the keynote speaker. I posted some highlights back then from the call. From memory and I could be off I am pretty sure he said he expected trogarzo to be 10x egrifta. The 1 billion in sales comes from the agreement when a higher payment kicks in. I don’t ever remember hearing him say he expects 1 billion in sales. That i would remember.

It was in a weekend newspaper article from November 2017 if I recall correctly.

bfw

Bullboard Posts

Gold vs. bitcoin, where should you invest?